Editorial: TNFRSF agonists: mode of action and therapeutic opportunities

• Nataša Obermajer,
• Adam Zwolak,
• Harald Wajant

Affiliations

Nataša Obermajer

Oncology R&D, Johnson and Johnson Innovative Medicine, Beerse, Belgium

Adam Zwolak

Therapeutics Discovery, Johnson and Johnson Innovative Medicine, Spring House, PA, United States

Harald Wajant

Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany